Newron Pharmaceuticals S.p.A. (0QOI.L)

CHF 7.54

(6.95%)

Revenue Summary of Newron Pharmaceuticals S.p.A.

  • Newron Pharmaceuticals S.p.A.'s latest annual revenue in 2023 was 9.05 Million EUR , up 48.62% from previous year.
  • Newron Pharmaceuticals S.p.A.'s latest quarterly revenue in 2024 Q2 was 3.4 Million EUR , down 0.0% from previous quarter.
  • Newron Pharmaceuticals S.p.A. reported a annual revenue of 6.09 Million EUR in annual revenue 2022, up 5.76% from previous year.
  • Newron Pharmaceuticals S.p.A. reported a annual revenue of 5.76 Million EUR in annual revenue 2021, up 9.59% from previous year.
  • Newron Pharmaceuticals S.p.A. reported a quarterly revenue of 5.49 Million EUR for 2023 Q2, down 0.0% from previous quarter.
  • Newron Pharmaceuticals S.p.A. reported a quarterly revenue of 9.05 Million EUR for 2023 FY, up 48.62% from previous quarter.

Annual Revenue Chart of Newron Pharmaceuticals S.p.A. (2023 - 2005)

Historical Annual Revenue of Newron Pharmaceuticals S.p.A. (2023 - 2005)

Year Revenue Revenue Growth
2023 9.05 Million EUR 48.62%
2022 6.09 Million EUR 5.76%
2021 5.76 Million EUR 9.59%
2020 5.25 Million EUR -25.29%
2019 7.03 Million EUR 74.86%
2018 4.02 Million EUR -70.03%
2017 13.42 Million EUR 99.64%
2016 6.72 Million EUR 182.61%
2015 2.38 Million EUR 52.86%
2014 1.55 Million EUR -56.0%
2013 3.53 Million EUR -60.34%
2012 8.92 Million EUR 3087.14%
2011 280 Thousand EUR -65.26%
2010 806 Thousand EUR -68.29%
2009 2.54 Million EUR -35.37%
2008 3.93 Million EUR -2.26%
2007 4.02 Million EUR 237.87%
2006 1.19 Million EUR 0.0%
2005 - EUR 0.0%

Peer Revenue Comparison of Newron Pharmaceuticals S.p.A.

Name Revenue Revenue Difference
Relief Therapeutics Holding AG 6.03 Million CHF -50.124%
Tecan Group AG 1.07 Billion CHF 99.157%
Santhera Pharmaceuticals Holding AG 103.41 Million CHF 91.242%
Basilea Pharmaceutica AG 157.63 Million CHF 94.254%
Bachem Holding AG 577.31 Million CHF 98.431%
Siegfried Holding AG 1.27 Billion CHF 99.288%
Molecular Partners AG 7.03 Million CHF -28.687%